WUXI BIOLOGICS (CAYMAN) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.74 HKD | -1.24% |
|
-3.78% | -56.96% |
Presenter SpeechZiyi Chen (Attendees)Good morning and good evening to all global investors. Th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
11.93
CNY
Average target price
26.4
CNY
Spread / Average Target
+121.21%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.96% | 6.86B | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.46% | 22.2B | |
| -16.53% | 21.23B | |
| -8.98% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- 2269 Stock
- News WuXi Biologics (Cayman) Inc.
- Transcript : WuXi Biologics Inc., Q2 2022 Earnings Call, Aug 18, 2022
